The hepatic
DNA of 12-day-old male B6C3F1 (C57BL/6J X C3H/HeJ) mice given an i.p. dose of 0.06 or 0.11 mumol/g
body weight of N-hydroxy-[3H]-
2-acetylaminofluorene (N-hydroxy-AAF) contained at 9 h approximately 3 or 6 pmol of
N-(deoxyguanosin-8-yl)-2-aminofluorene adducts per mg. Together the level of the two acetylated adducts N-(deoxyguanosin-8-yl)-2-acetylaminofluorene and
3-(deoxyguanosin-N2-yl)-2-acetylaminofluorene was less than or equal to 10% of this amount. The same doses of unlabeled
carcinogen induced by 10 months a 100% incidence of
hepatomas with averages of 10 and 15
hepatomas per mouse, respectively. Injection of 0.04 mumol/g
body weight of
pentachlorophenol (PCP) 45 min before the dose of N-hydroxy-AAF decreased the number of adducts in the
DNA by 90% and the average number of
hepatomas per liver by 80-90%. As compared to their normal male littermates, male brachymorphic B6C3F2 mice, which are deficient in hepatic 3'-phosphoadenosine-5'-phosphosulfate (PAPS), treated with N-hydroxy-AAF formed only 25% as many hepatic
DNA adducts and developed only 10% as many
hepatomas. Hepatic cytosols from 12-day-old B6C3F1 mice contained PAPS-dependent
sulfotransferase activity for
N-hydroxy-2-aminofluorene (N-hydroxy-AF), a previously unrecognized activity, as well as
sulfotransferase activity for N-hydroxy-AAF; both activities were inhibited 60% by 1 microM and greater than or equal to 80% by 10 microM PCP. Cytosolic
acetyl coenzyme A-dependent
acetyltransferase activity for N-hydroxy-AF, cytosolic N,O-
acyltransferase activity for N-hydroxy-AAF, and microsomal deacetylase for N-hydroxy-AAF were not significantly inhibited by PCP under these conditions. The above data strongly indicate that N-sulfoöxy-2-aminofluorene is the major ultimate electrophilic and carcinogenic metabolite of N-hydroxy-AAF in the livers of infant male B6C3F1 mice.